USAN Watch - August 2010
| USAN | Research code | Drug Type | Drug Class | Target |
| Alvocidib | Flavopiridol, HL-275, HMR-1275, L86-8275, MDL-107826A, NSC-649890 | Synthetic small molecule | therapeutic | CDK inhibitor |
| Danoprevir | R05190591, RG-7227, ITMN-191 | Synthetic small molecule | therapeutic | HCV Proteinase inhibitor |
| Latrepiridine | Synthetic small molecule | therapeutic | Complex MOA | |
| Lunacalcipol | CTA-018 | Natural product-derived | therapeutic | Vitamin D receptor |
| Mavrilimumab | CAM-3001 | mAb | therapeutic | GMCSFr alpha-chain |
| Moxetumomab pasudotox | CAT-8015, HA22 | mAb | therapeutic | CD-22 |
| Semuloparin sodium | AVE-5026 | Oligosaccharide | therapeutic | Antithrombin III |
It may be of interest to note the USANs "Semuloparin" and "Semuloparin Sodium" in July and August this year. These USANs refer to the same active substance (Semuloparin), one being the sodium salt of the other. There are slight differences that exist between the WHO INN process and the USAN process. INNs do not include the salt/counterion in the name, whereas USANs historically have. Now, for USANs, both the salt and the parent molecule get assigned distinct USANs.